The Eyes Have It: Eyelid Swelling and Rash in a 79-year-old Woman With Macular Degeneration.

IF 2.3 Q1 OTORHINOLARYNGOLOGY
Allergy & Rhinology Pub Date : 2018-05-01 eCollection Date: 2018-01-01 DOI:10.1177/2152656718763385
Renee S Kleris, Anjeni Keswani, Patricia Lugar
{"title":"The Eyes Have It: Eyelid Swelling and Rash in a 79-year-old Woman With Macular Degeneration.","authors":"Renee S Kleris,&nbsp;Anjeni Keswani,&nbsp;Patricia Lugar","doi":"10.1177/2152656718763385","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>A 79-year-old woman with macular degeneration was referred to the Allergy/Immunology clinic for the evaluation of a potential allergy to anti-vascular endothelial growth factor (anti-VEGF) treatments. The patient developed urticaria and eyelid swelling immediately following a retinal injection of aflibercept, which she had previously tolerated. She previously had allergic reactions following ranibizumab and bevacizumab injections. Injections of anti-VEGF treatments were discontinued given concern for allergy with progression of the patient's disease.</p><p><strong>Objective: </strong>To assess the culprit medication(s) responsible for hypersensitivity reactions following anti-VEGF injections for macular degeneration.</p><p><strong>Methods: </strong>Medication records were reviewed for each retinal injection. All medications used in each procedure, including the anti-VEGF therapy (aflibercept), topical anesthetics (tetracaine and proparacaine hydrochloride), and antiseptic (povidine), were evaluated with skin testing. She was additionally tested for alternative anti-VEGF therapies (ranibizumab and bevacizumab) as she was thought to have allergies to these agents by prior history. A test dose challenge was completed for aflibercept, ranibizumab, and bevacizumab.</p><p><strong>Results: </strong>Skin prick and intradermal testing were negative to aflibercept, ranibizumab, bevacizumab, and povidine. Intradermal testing was positive to tetracaine and proparacaine hydrochloride. The patient passed test dose challenges to aflibercept, ranibizumab, and bevacizumab. Due to her positive hypersensitivity testing to 2 ester anesthetics, the patient underwent skin prick and intradermal testing to the amide anesthetic, lidocaine. This was negative and the patient tolerated a graded challenge to lidocaine. She was deemed to have an immunoglobulin E (IgE)-mediated hypersensitivity to ester-type local anesthetics. She successfully resumed anti-VEGF therapy with an amide local anesthetic.</p><p><strong>Conclusions: </strong>The reason for this consult was the concern for hypersensitivity to a biologic anti-VEGF medication. The culprit allergen, the local anesthetic, could have been overlooked without an assessment of all medications used during the procedure. This case highlights the importance of a thorough allergy evaluation of all medications used during procedures to determine the causative agent.<b>Chief Complaint:</b> Eyelid swelling and rash after ophthalmic procedures for macular degeneration.</p>","PeriodicalId":45192,"journal":{"name":"Allergy & Rhinology","volume":"9 ","pages":"2152656718763385"},"PeriodicalIF":2.3000,"publicationDate":"2018-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/2152656718763385","citationCount":"6","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Allergy & Rhinology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/2152656718763385","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2018/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"OTORHINOLARYNGOLOGY","Score":null,"Total":0}
引用次数: 6

Abstract

Introduction: A 79-year-old woman with macular degeneration was referred to the Allergy/Immunology clinic for the evaluation of a potential allergy to anti-vascular endothelial growth factor (anti-VEGF) treatments. The patient developed urticaria and eyelid swelling immediately following a retinal injection of aflibercept, which she had previously tolerated. She previously had allergic reactions following ranibizumab and bevacizumab injections. Injections of anti-VEGF treatments were discontinued given concern for allergy with progression of the patient's disease.

Objective: To assess the culprit medication(s) responsible for hypersensitivity reactions following anti-VEGF injections for macular degeneration.

Methods: Medication records were reviewed for each retinal injection. All medications used in each procedure, including the anti-VEGF therapy (aflibercept), topical anesthetics (tetracaine and proparacaine hydrochloride), and antiseptic (povidine), were evaluated with skin testing. She was additionally tested for alternative anti-VEGF therapies (ranibizumab and bevacizumab) as she was thought to have allergies to these agents by prior history. A test dose challenge was completed for aflibercept, ranibizumab, and bevacizumab.

Results: Skin prick and intradermal testing were negative to aflibercept, ranibizumab, bevacizumab, and povidine. Intradermal testing was positive to tetracaine and proparacaine hydrochloride. The patient passed test dose challenges to aflibercept, ranibizumab, and bevacizumab. Due to her positive hypersensitivity testing to 2 ester anesthetics, the patient underwent skin prick and intradermal testing to the amide anesthetic, lidocaine. This was negative and the patient tolerated a graded challenge to lidocaine. She was deemed to have an immunoglobulin E (IgE)-mediated hypersensitivity to ester-type local anesthetics. She successfully resumed anti-VEGF therapy with an amide local anesthetic.

Conclusions: The reason for this consult was the concern for hypersensitivity to a biologic anti-VEGF medication. The culprit allergen, the local anesthetic, could have been overlooked without an assessment of all medications used during the procedure. This case highlights the importance of a thorough allergy evaluation of all medications used during procedures to determine the causative agent.Chief Complaint: Eyelid swelling and rash after ophthalmic procedures for macular degeneration.

Abstract Image

眼睛有它:眼睑肿胀和皮疹的79岁妇女与黄斑变性。
简介:一位79岁的黄斑变性女性被转介到过敏/免疫学诊所,评估对抗血管内皮生长因子(anti-VEGF)治疗的潜在过敏。患者在先前耐受的阿夫利西普视网膜注射后立即出现荨麻疹和眼睑肿胀。她曾在注射雷尼单抗和贝伐单抗后出现过敏反应。停止注射抗vegf治疗,考虑到患者疾病进展的过敏。目的:探讨黄斑变性患者注射抗vegf后过敏反应的罪魁祸首药物。方法:回顾每次视网膜注射的用药记录。每个手术中使用的所有药物,包括抗vegf疗法(阿布西普)、表面麻醉剂(丁卡因和盐酸丙帕卡因)和防腐剂(聚维定),均通过皮肤试验进行评估。她还接受了替代抗vegf治疗(雷尼单抗和贝伐单抗)的测试,因为她之前的病史被认为对这些药物过敏。完成了阿非利塞普、雷尼单抗和贝伐单抗的试验剂量挑战。结果:皮肤点刺和皮内试验对阿非利塞普、雷尼单抗、贝伐单抗和普维定均阴性。皮内试验对丁卡因和盐酸丙帕卡因阳性。患者通过了阿非利塞普、雷尼单抗和贝伐单抗的试验剂量挑战。由于她对2种酯类麻醉剂过敏试验阳性,患者接受了对酰胺类麻醉剂利多卡因的皮肤穿刺和皮内试验。结果为阴性,患者耐受利多卡因的分级挑战。她被认为对酯型局麻药有免疫球蛋白E (IgE)介导的超敏反应。她用酰胺局部麻醉成功恢复抗vegf治疗。结论:咨询的原因是担心对生物抗vegf药物过敏。如果没有对手术过程中使用的所有药物进行评估,罪魁祸首过敏原——局部麻醉剂可能会被忽视。本病例强调了在确定致病因子的过程中对所有药物进行全面过敏评估的重要性。主诉:黄斑变性眼科手术后眼睑肿胀和皮疹。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Allergy & Rhinology
Allergy & Rhinology OTORHINOLARYNGOLOGY-
CiteScore
3.30
自引率
4.50%
发文量
11
审稿时长
15 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信